XML 26 R33.htm IDEA: XBRL DOCUMENT

Variable Interest Entities (Tables) - Cleco Power [Member]

9 Months Ended

Sep. 30, 2015

Variable Interest Entity [Line Items]

Comparison of Investee's Assets and Liabilities with Maximum Exposure to Loss

The following table compares the carrying amount of Oxbow’s assets and liabilities with Cleco Power’s maximum exposure to loss related to its investment in Oxbow:



(THOUSANDS)	AT SEPT. 30, 2015		AT DEC. 31, 2014
Oxbow’s net assets/liabilities	$	32,745	$	29,065
Cleco Power’s 50% equity	$	16,372	$	14,532
Cleco Power’s maximum exposure to loss	$	16,372	$	14,532

Equity Method Investments

The following tables contain summarized financial information for Oxbow:



(THOUSANDS)	AT SEPT. 30, 2015		AT DEC. 31, 2014
Current assets	$	2,159	$	2,792
Property, plant, and equipment, net	23,806		22,457
Other assets	7,446		3,847
Total assets	$	33,411	$	29,096
Current liabilities	$	666	$	31
Partners’ capital	32,745		29,065
Total liabilities and partners’ capital	$	33,411	$	29,096



	FOR THE THREE MONTHS ENDED SEPT. 30,				FOR THE NINE MONTHS ENDED SEPT. 30,
(THOUSANDS)	2015		2014		2015		2014
Operating revenue	$	942	$	584	$	2,656	$	1,595
Operating expenses	942		584		2,656		1,595
Income before taxes	$	—	$	—	$	—	$	—

The following table presents the components of Cleco Power’s equity investment in Oxbow:



INCEPTION TO DATE (THOUSANDS)	AT SEPT. 30, 2015		AT DEC. 31, 2014
Purchase price	$	12,873	$	12,873
Cash contributions	3,499		1,659
Total equity investment in investee	$	16,372	$	14,532

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details